Bimal Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 11-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 11-07-2024
- Company Age 22 Year, 12 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.41 Cr
as on 11-07-2024
- Satisfied Charges ₹ 2.85 Cr
as on 11-07-2024
- Revenue 105.74%
(FY 2022)
- Profit 40.44%
(FY 2022)
- Ebitda -784.98%
(FY 2022)
- Net Worth 21.45%
(FY 2022)
- Total Assets 69.08%
(FY 2022)
About Bimal Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹6.41 Cr. The company has closed loans amounting to ₹2.85 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jagdish Parikh and Kundan Parikh serve as directors at the Company.
- CIN/LLPIN
U51397MH2002PTC137273
- Company No.
137273
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bimal Pharma Private Limited offer?
Bimal Pharma Private Limited offers a wide range of products and services, including Industrial Acid, Hydrochloric Acid, White Pigments, Titanium Dioxide.
Who are the key members and board of directors at Bimal Pharma?
Board Members(2)
Financial Performance and Corporate Structure Insights of Bimal Pharma.
Bimal Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 105.74% increase. The company also saw a substantial improvement in profitability, with a 40.44% increase in profit. The company's net worth Soared by an impressive increase of 21.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bimal Pharma?
Unlock access to Bimal Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Jan 2005 | ₹3.91 Cr | Open |
Sbi Factors And Commercial Services Ltd. Creation Date: 09 Sep 2004 | ₹2.50 Cr | Open |
The Saraswat Co - Op. Bank Ltd. Creation Date: 30 Dec 2003 | ₹1.50 M | Satisfied |
How Many Employees Work at Bimal Pharma?
Unlock and access historical data on people associated with Bimal Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Jan 05, 2013, Bimal Pharma has raised a total of ₹ 10 M, with the most recent deal valued at ₹ 10 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
